EU Fast-Track Loss For Vertex’s CF Triple Combo
Company Needs Time To Prepare Further Data For Trikafta MAA
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
